757 High ESR1 and PGR mRNA expression determined by RT-qPCR in FFPE routine tissue samples predicts superior disease specific survival in non-muscle invasive bladder cancer

2015 ◽  
Vol 14 (2) ◽  
pp. e757
Author(s):  
J. Breyer ◽  
M. Burger ◽  
S. Denzinger ◽  
S. Herlein ◽  
R. Stöhr ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mrna Expression ◽  
Invasive Bladder Cancer ◽  
Disease Specific Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Tissue Samples ◽  
Muscle Invasive ◽  
Disease Specific

scholarly journals Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sebastien Rinaldetti ◽  
Thomas Stefan Worst ◽  
Eugen Rempel ◽  
Maximilian C. Kriegmair ◽  
Arndt Hartmann ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Subtype ◽  
Invasive Bladder Cancer ◽  
Survival Prediction ◽  
Disease Specific Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Specific Expression ◽  
Cancer Subtypes ◽  
Muscle Invasive ◽  
Disease Specific

AbstractComprehensive transcriptome expression analyses of bladder cancer revealed distinct lncRNA clusters with differential molecular and clinical characteristics. In this study, pivotal lncRNAs were assessed for their impact on survival and their differential expression between the molecular bladder cancer subtypes. FFPE samples from chemotherapy-naïve patients with muscle invasive bladder cancer (MIBC) were analyzed on the Nanostring nCounter platform for absolute quantification. An established 36-gene panel was used for molecular subtype classification into basal, luminal and infiltrated MIBC. In a second step, 14 pivotal lncRNAs were assessed for their molecular subtype attribution, and their predictive value in disease-specific survival. In silico validation was performed on a total of 487 MIBC patients (MDA, TGCA and Chungbuk cohort). Several pivotal lncRNAs showed a distinct molecular subtype attribution: e.g. MALAT1 showed a downregulation in the basal subtype (p = 0.009), TUG1 and CBR3AS1 showed an upregulation in the luminal subtype (p ≤ 0.001). High transcript levels of SNHG16, CBR3AS1 and H19 appeared to be predictive for a shorter disease-specific survival. Patients overexpressing putative oncogenes MALAT1 and TUG1 in MIBC tissue presented prolonged survival, suggesting tumor suppressive effects of both lncRNAs. The Nanostring nCounter proved to be a valid platform for the quantification of low-abundance transcripts including lncRNAs.

Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year Outcome

2001 ◽  
Vol 19 (1) ◽  
pp. 89-93 ◽  
Author(s):  
Harry W. Herr
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Residual Tumor ◽  
Invasive Bladder Cancer ◽  
Tumor Site ◽  
Disease Specific Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Primary Tumor Site ◽  
Muscle Invasive ◽  
Disease Specific

PURPOSE: To determine the 10-year outcome of patients with muscle-invasive bladder cancer treated by transurethral resection (TUR) alone. PATIENTS AND METHODS: Of 432 newly evaluated patients with muscle-invasive bladder cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TUR of the primary tumor site showed no (T0) or only non–muscle-invasive (T1) residual tumor. Patients were followed-up every 3 to 6 months thereafter for a minimum of 10 years and up to 20 years. Primary end points of the study were disease-specific survival, survival with a bladder, frequency of recurrent invasive tumors in the bladder, and survival after salvage cystectomy. RESULTS: The 10-year disease-specific survival was 76% of 99 patients who received TUR as definitive therapy (57% with bladder preserved) compared with 71% of 52 patients who had immediate cystectomy (P = .3). Of the 99 patients treated with TUR, 82% of 73 who had T0 on restaging TUR survived versus 57% of the 26 patients who had residual T1 tumor on restaging TUR (P = .003). Thirty-four patients (34%) relapsed in the bladder with a new muscle-invasive tumor, 18 (53%) were successfully treated with salvage therapy via cystectomy, and 16 patients (16%) died of disease. CONCLUSION: Radical TUR for muscle-invasive bladder cancer is a successful bladder-sparing therapeutic strategy in selected patients who have no residual tumor on a repeat vigorous resection of the primary tumor site.

Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 562-562
Author(s):  
Florian Roghmann ◽  
Moritz Reike ◽  
Ralph Wirtz ◽  
Maximilian Kriegmair ◽  
Philipp Erben ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mrna Expression ◽  
Expression Patterns ◽  
High Risk Group ◽  
Invasive Bladder Cancer ◽  
Study Cohort ◽  
Muscle Invasive Bladder Cancer ◽  
Tissue Samples ◽  
Muscle Invasive

562 Background: Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival. Those with a pathological complete response (pCR) usually have the best prognosis. In the literature, improved response to NAC has been associated with basal tumor characteristics in MIBC so far. The aim of the present study was to examine the association of luminal (KRT20) and basal (KRT5) mRNA expression patterns at transurethral resection (TUR) with pCR at RC after NAC in a contemporary cohort of consecutive MIBC patients. Methods: Clinical Data and formalin fixed paraffin embedded tumor tissue samples from TUR and RC of 49 patients with MIBC were retrospectively analyzed. Using RT-PCR KRT20 and KRT5 mRNA expression were measured in 40-∆Ct values and normalized against the control gene CALM2. Statistical analyses comprised nonparametric and chi2 testing, partition models and spearman correlation analyses. Results: The study cohort had a median age of 63 years and consisted of 38/49 (78%) males. After NAC, 17/49 (35%) patients had cPR. Using partition models, we found that patients with high-KRT20 (≥39.5 ∆Ct) had a higher chance of pCR (57% vs. 26%, p=0.04). Using a cutoff for KRT5 at <38.1 ∆Ct within the subgroup of patients with low-KRT20 (<39.5 ∆Ct, n=35), we found poorest response among low-KRT20/low-KRT5 compared to low-KRT20/high-KRT5 and high-KRT20 (13% vs. 37% vs. 57%, p=0.29), respectively. For low-KRT20/low-KRT5, low-KRT20/high-KRT5 and high-KRT20 median KRT5 was 34.8 vs. 39.5 vs. 34.1 ∆Ct ( p=0.001) and median KRT20 was 37.9 vs. 32.9 vs. 40.1 ∆Ct,( p=0.001), respectively. Conclusions: Patients with MIBC showing high expression of KRT20 were more likely to show pCR at RC after NAC. Moreover, we were able to identify a high risk group of patients with lowKRT20/lowKRT5 that was less likely to achieve pCR at RC after NAC. Our findings are contradicting previous studies and need further verification in larger cohorts. However, our results might be useful for treatment stratification in MIBC patients.

scholarly journals Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1624
Author(s):  
Christos G. Gavriel ◽  
Neofytos Dimitriou ◽  
Nicolas Brieu ◽  
Ines P. Nearchou ◽  
Ognjen Arandjelović ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Statistical Significance ◽  
Tnm Staging ◽  
Cancer Prognosis ◽  
Clinical Staging ◽  
Invasive Bladder Cancer ◽  
P Value ◽  
Muscle Invasive Bladder Cancer ◽  
Tissue Samples ◽  
Muscle Invasive

The clinical staging and prognosis of muscle-invasive bladder cancer (MIBC) routinely includes the assessment of patient tissue samples by a pathologist. Recent studies corroborate the importance of image analysis in identifying and quantifying immunological markers from tissue samples that can provide further insight into patient prognosis. In this paper, we apply multiplex immunofluorescence to MIBC tissue sections to capture whole-slide images and quantify potential prognostic markers related to lymphocytes, macrophages, tumour buds, and PD-L1. We propose a machine-learning-based approach for the prediction of 5 year prognosis with different combinations of image, clinical, and spatial features. An ensemble model comprising several functionally different models successfully stratifies MIBC patients into two risk groups with high statistical significance (p value < 1×10−5). Critical to improving MIBC survival rates, our method correctly classifies 71.4% of the patients who succumb to MIBC, which is significantly more than the 28.6% of the current clinical gold standard, the TNM staging system.

Sign in / Sign up

Export Citation Format

Share Document